Molecular Profile Detail

Profile Name KDR A1065T
Gene Variant Detail

KDR A1065T (gain of function - predicted)

Relevant Treatment Approaches VEGFR Inhibitor (Pan) VEGFR2 Inhibitor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
KDR A1065T Advanced Solid Tumor sensitive VEGFR2 Inhibitor Sunitinib Preclinical Actionable In a preclinical study, cells expressing KDR A1065T were sensitive to Sutent (sunitinib) in culture (PMID: 19723655). 19723655
Clinical Trial Phase Therapies Title Recruitment Status